Sicart Associates’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12M | Sell |
159,412
-4,145
| -3% | -$327K | 3.08% | 8 |
|
|
2025
Q4 | $12.9M | Sell |
163,557
-761
| -0.5% | -$57.3K | 3.43% | 6 |
|
|
2025
Q3 | $10.7M | Sell |
164,318
-20,978
| -11% | -$1.02M | 2.91% | 11 |
|
|
2025
Q2 | $7.32M | Sell |
185,296
-350
| -0.2% | -$11.5K | 2.56% | 14 |
|
|
2025
Q1 | $5.6M | Sell |
185,646
-175
| -0.1% | -$5.73K | 1.94% | 22 |
|
|
2024
Q4 | $6.5M | Sell |
185,821
-5,702
| -3% | -$213K | 2.32% | 17 |
|
|
2024
Q3 | $7.67M | Hold |
191,523
| – | – | 2.69% | 14 |
|
|
2024
Q2 | $9.13M | Sell |
191,523
-2,470
| -1% | -$101K | 3.5% | 7 |
|
|
2024
Q1 | $8.41M | Sell |
193,993
-300
| -0.2% | -$14.3K | 3.08% | 11 |
|
|
2023
Q4 | $9.83M | Sell |
194,293
-8,839
| -4% | -$423K | 3.76% | 6 |
|
|
2023
Q3 | $9.21M | Sell |
203,132
-1,815
| -0.9% | -$74.9K | 3.61% | 9 |
|
|
2023
Q2 | $8.41M | Sell |
204,947
-5,751
| -3% | -$221K | 3.27% | 10 |
|
|
2023
Q1 | $7.53M | Sell |
210,698
-35,560
| -14% | -$1.34M | 2.93% | 11 |
|
|
2022
Q4 | $9.3M | Sell |
246,258
-7,718
| -3% | -$325K | 3.28% | 9 |
|
|
2022
Q3 | $11.2M | Sell |
253,976
-34,775
| -12% | -$1.47M | 3.98% | 5 |
|
|
2022
Q2 | $10.7M | Sell |
288,751
-16,031
| -5% | -$605K | 3.33% | 8 |
|
|
2022
Q1 | $11.3M | Buy |
304,782
+22,251
| +8% | +$728K | 2.92% | 9 |
|
|
2021
Q4 | $8.63M | Sell |
282,531
-8,723
| -3% | -$275K | 2.25% | 16 |
|
|
2021
Q3 | $9.77M | Sell |
291,254
-77,155
| -21% | -$2.91M | 2.66% | 14 |
|
|
2021
Q2 | $14.7M | Sell |
368,409
-1,889
| -0.5% | -$74K | 3.5% | 8 |
|
|
2021
Q1 | $16.6M | Sell |
370,298
-32,610
| -8% | -$1.82M | 4.4% | 5 |
|
|
2020
Q4 | $22.8M | Sell |
402,908
-15,387
| -4% | -$767K | 5.62% | 2 |
|
|
2020
Q3 | $19.8M | Sell |
418,295
-1,077
| -0.3% | -$59.8K | 5.93% | 3 |
|
|
2020
Q2 | $24.7M | Sell |
419,372
-10,380
| -2% | -$577K | 7.91% | 2 |
|
|
2020
Q1 | $20.3M | Buy |
429,752
+18,940
| +5% | +$1.06M | 7.74% | 2 |
|
|
2019
Q4 | $24.8M | Buy |
410,812
+275
| +0.1% | +$16.4K | 8.27% | 1 |
|
|
2019
Q3 | $24.6M | Sell |
410,537
-2,835
| -0.7% | -$185K | 8.07% | 1 |
|
|
2019
Q2 | $26.6M | Sell |
413,372
-3,613
| -0.9% | -$255K | 10.8% | 1 |
|
|
2019
Q1 | $33.8M | Sell |
416,985
-104,974
| -20% | -$6.77M | 14.3% | 1 |
|
|
2018
Q4 | $28.2M | Sell |
521,959
-1,885
| -0.4% | -$96.1K | 13.66% | 1 |
|
|
2018
Q3 | $27M | Sell |
523,844
-50
| -0% | -$2.35K | 12.96% | 1 |
|
|
2018
Q2 | $21.8M | Buy |
523,894
+177,082
| +51% | +$7.85M | 11.45% | 1 |
|
|
2018
Q1 | $15.3M | Sell |
346,812
-51,260
| -13% | -$2.6M | 9.13% | 2 |
|
|
2017
Q4 | $20M | Buy |
398,072
+9,050
| +2% | +$496K | 10.57% | 1 |
|
|
2017
Q3 | $19.7M | Buy |
389,022
+1,700
| +0.4% | +$89K | 14.11% | 1 |
|
|
2017
Q2 | $19.7M | Buy |
387,322
+19,962
| +5% | +$930K | 14.32% | 1 |
|
|
2017
Q1 | $14.8M | Buy |
367,360
+87,045
| +31% | +$3.91M | 10.67% | 1 |
|
|
2016
Q4 | $13.4M | Buy |
+280,315
| New | +$11.1M | 9.25% | 1 |
|
Other funds holding IONS
VPM
VCM
Sicart Associates's IONS Position: Q1 2026 in Review
Sicart Associates reduced its Ionis Pharmaceuticals (IONS) stake by 2.5% in Q1 2026, selling an estimated $327K and leaving 159,412 shares worth $12M. The position accounts for 3.08% of the portfolio, ranked #8.
Sicart Associates first reported a position in IONS in Q4 2016 and has held it in 38 quarters since. The position peaked at $33.8M in Q1 2019. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Sicart Associates held 159,412 shares of Ionis Pharmaceuticals worth $12M as of Q1 2026.
- Sicart Associates sold 4,145 Ionis Pharmaceuticals shares in Q1 2026, an estimated $327K.
- Ionis Pharmaceuticals made up 3.08% of Sicart Associates's portfolio in Q1 2026, its #8 holding.
- Sicart Associates first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
- Sicart Associates's Ionis Pharmaceuticals position peaked at $33.8M in Q1 2019.
- 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Sicart Associates's 13F filing for Q1 2026, filed 21 Apr 2026.